Recordati Ireland Ltd.
Records under this name other than the patents Recordati Ireland Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 10 of 10 · Back to Recordati Ireland Ltd.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,593,127 | HETEROCYCLYLALKYNE DERIVATIVES AND THEIR USE AS MODULATORS OF mGluR5 RECEPTORS Lapsed on the fee record Ended Mar 14, 2025 · High confidence | Lapsed on the fee record | Ended Mar 14, 2025 | High confidence |
| US 9,889,121 | Heterocyclylalkyne Derivatives and Their Use as Modulators of MGLUR5 Receptors Lapsed on the fee record Ended Feb 13, 2022 · High confidence | Lapsed on the fee record | Ended Feb 13, 2022 | High confidence |
| US 8,580,962 | Spiroheterocyclic compounds as mGlu5 antagonists Lapsed on the fee record Ended Nov 12, 2021 · From the USPTO record | Lapsed on the fee record | Ended Nov 12, 2021 | From the USPTO record |
| US 6,333,044 | Therapeutic compositions for intranasal administration which include KETOROLAC.RTM. Formerly held Term ended Term ended Dec 25, 2018 · From the USPTO record | Term ended | Term ended Dec 25, 2018 | From the USPTO record |
| US 7,683,179 | Lercanidipine salts Lapsed on the fee record Ended Mar 23, 2018 · From the USPTO record | Lapsed on the fee record | Ended Mar 23, 2018 | From the USPTO record |
| US 8,518,916 | Heterocyclic derivatives as M-GLU5 antagonists Lapsed on the fee record Ended Aug 27, 2017 · From the USPTO record | Lapsed on the fee record | Ended Aug 27, 2017 | From the USPTO record |
| US 6,852,737 | Crude and crystalline forms of lercanidipine hydrochloride Lapsed on the fee record Ended Feb 8, 2017 · From the USPTO record | Lapsed on the fee record | Ended Feb 8, 2017 | From the USPTO record |
| US 7,267,827 | Therapeutic compositions for intranasal administration which include KETOROLAC Formerly held Term ended Term ended Sep 6, 2015 · From the USPTO record | Term ended | Term ended Sep 6, 2015 | From the USPTO record |
| US 7,476,689 | Therapeutic compositions for intranasal administration which include KETOROLAC Formerly held Term ended Term ended Oct 11, 2012 · From the USPTO record | Term ended | Term ended Oct 11, 2012 | From the USPTO record |
| US 5,798,362 | Quinazolinyl-amino derivatives having .alpha.-antagonist activity Term ended Term ended no later than Aug 25, 2018 · Low confidence | Term ended | Term ended no later than Aug 25, 2018 | Low confidence |